Metabolic Effects of Bendroflumethiazide in Patient, with Recurrent Calcium Oxalate Stone Disease

Publisher Website
Google Scholar
Abstract
Two groups of patients with urolithiasis were treated with 2.5 mg (group A) and 5.0 mg (group B) bendroflumethiazide daily. There were 14 men and 3 women in group A, and 14 men and 2 women in group B in whom metabolic effects were followed during 1 yr of treatment. Serum Ca was significantly increased in group B after 1 mo. but later returned to the pre-treatment level. A significant decrease in serum Mg was recorded in group B after 6 and 12 mo. No significant effect on serum Ca or Mg was observed in group A. Serum K decreased in both groups but serum urate remained at the pre-treatment level. An increased alkalinity was noted in both groups. Urinary Ca was decreased significantly only in group B. Although significantly increased excretion of Mg was observed after 1 and 6 mo. in group A this was not encountered in group B, and after 12 mo. urinary Mg was at the pre-treatment level in both groups. Urinary excretion of oxalate, urate and citrate appeared to be unaffected by the treatment. The inhibition of calcium oxalate crystal growth and urine volume did not change. The Ca/Mg quotient decreased in both groups as did the Ca times oxalate/Mg quotient. The main metabolic effect of bendroflumethiazide, with respect to its stone prophylactic property, appears to be a decrease in the Ca/Mg quotient and a dose of 5 mg/day probably is more satisfactory than a 2.5 mg dose.